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Abstract 
The role of the Protein Kinase CKII in the life cycle of Human Papillomaviruses 
Cervical cancer is the fourth most common cancer in women and virtually all cases can be 
traced back to a preceding infection with a high-risk HPV (human papillomavirus) type. 
Worldwide 10% of all women are infected, with the hotspots being South America and Africa. 
The best way to fight cervical cancer is to prohibit its formation. Currently, only vaccines are 
available to achieve this, but these are not the ultimate solution, as they are not able to clear an 
existing HPV infection. If we want to reduce the cancer risk of the millions of women infected 
with HPV today, we need a supplement, which is able to clear a persisting HPV infection 
reliably. In this thesis it is shown that the catalytic subunit of the protein kinase CK2 plays an 
important role in the initial amplification phase of HPV and an interference leads to lesser 
replication rates of viral genomes. Additionally, a CK2 inhibitor (CX-4945) is tested for its 
ability to inhibit CK2 and through this to hinder HPV replication. It is shown that this compound 
could be the basis for the long sought anti-HPV drug. 
key words: HPV, HPV replication, protein kinase CK2, CK2α, CX-4945  
CERCS code: B230 (microbiology, bacteriology, virology, mycology) 
 
Kokkuvõte 
Proteiinkinaas CK2-e roll inimese papilloomiviiruse elutsüklis 
Emakakaelavähk on maailmas levimuselt neljas vähiliik ning peaaegu kõiki juhtumeid 
põhjustab varasem infektsioon inimese papilloomiviirusega. Üle maailma on sellega nakatanud 
ligikaudu 10% kõikidest naistest. Parim viis emakakaelavähi vastu võitlemiseks, on selle 
arenemise takistamine, kuid tänapäevani on vaktsineerimine HPV (ingl. k. human 
papillomavirus) vastu ainuke ennetusmeetod. Vaktsineerimine ei tõkesta aga olemasolevat 
nattust ning vaktsiinide kättesaadavus arengumaades on piiratud. See tähendab, et kui tahame 
vähendada miljonite naiste emakakaelavähki haigestumine, siis on vaja ravimit, mis suudaks 
käimasoleva HPV infektsiooni kõrvaldada. Käesolevas töös näidati, et proteiinkinaas CK2-e 
katalüütiline subühik omab tähtsat rolli HPV algses amplifikatsiooni faasis. Selle ensüümi tööd 
häirides, saab viiruse genoomi replikatsiooni taset efektiivselt alandada. Lisaks  katsetati CK2-
e inhibiitori (CX-4945) võimet läbi CK2-e inhibeerimise HPV replikatsiooni takistada. Leiti, et 
just CX-4945 võiks olla potentsiaalse HPV vastase ravimi baasiks. 
märksõnad: HPV, HPV replikatsioon, proteiinkinaas CK2, CK2α, CX-4945 
CERCS-i kood: B230 (mikrobioloogia, bakterioloogia, viroloogia, mükoloogia) 
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Used abbreviations 
AMP – ampicillin  
ATM – ataxia telangiectasia mutated 
BPV – bovine papillomavirus 
CDC – Centers for Disease Control and Prevention (USA) 
CK2 – casein kinase 2 
CK2 – casein kinase 2 subunit alpha 
CK2’ – casein kinase 2 subunit alpha prime 
CK2 – casein kinase 2 subunit beta 
CMV –  cytomegalovirus 
CRISPR/Cas – Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR 
associated nucleases 
CX-4945 – 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid 
DMEM – Dulbecco/Vogt modified Eagle's minimal essential medium 
ECL – enhanced chemiluminescence  
EBV – Epstein–Barr virus 
FCS – foetal calf serum 
HPV – human papillomavirus 
IC50 – half maximal inhibitory concentration 
IMDM – Iscove’s modified Dulbecco’s medium 
KM – kanamycin  
LB – lysogenic broth 
p53 – cellular tumour antigen p53 
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PDB – RCSB Protein Data Bank 
PDZ – acronym combining the first letters of three proteins – PSD95, Dlg1, zo-1 
pRb – retinoblastoma protein 
PV – papillomavirus 
siRNA – small interfering RNA 
TB – terrific broth 
TBP – TATA-Box binding protein 
URR – upstream regulatory region 
WHO – World Health Organisation 
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Introduction 
Human Papillomaviruses (HPV) are small DNA viruses that infect various epithelial tissues. 
HPV infections are normally cleared within a few months, without any symptoms appearing, 
however, in some rare cases, genital warts, benign tumours, or even cervical cancer develop. 
These HPV types, which are known to cause cancer, are called high-risk types. HPV infections 
are a pandemic issue and worldwide 10% of women carry the virus. This is especially a problem 
in the less-developed regions of the world, where the infection rate is high and systems for 
cancer screenings are not implemented. Almost all cervical cancer cases can be traced back to 
a previous infection with different risk types of human papillomaviruses. Cervical cancer is 
worldwide the fourth most common cancer in women and every year roughly 500 000 women 
are diagnosed, while 270 000 die, which accounts for about 7.5% of all cancer deaths. To this 
day there is no drug available that would heal an HPV infection, although the demand for one 
is huge.  
 
In this thesis the importance of the protein kinase CK2 in early HPV replication is investigated. 
In addition, the effect of an CK2 inhibitor (CX-4945) is tested, as this compound could be used 
in the first anti-HPV drug. The fact that CX-4945 reached the second phase in clinical trials 
already as an anti-cancer drug makes this even more promising. 
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Literature overview 
1. Human papillomaviruses (HPV) 
The human papillomaviruses are DNA viruses that belong to the Papillomaviridae family and 
are subdivided into five genera: -papillomaviruses (Alpha-PV), -papillomaviruses (Beta-
PV), -papillomaviruses (Gamma-PV), -papillomaviruses (Mu-PV) and -papillomaviruses 
(Nu-PV). The HPV classification into first genera and then species and types is based on 
sequence similarities in the L1 region of the HPV genome (see chapter 1.2 HPV genome), 
which is highly conserved. Up-to-date there are over 200 different HPV types described 
(Kocjan et al., 2015).  
Viruses of different genera infect different parts of the human body, for example, viruses of the 
-genera infect mucosal while viruses of the -, -, -, or -genera infect cutaneous tissues. 
From this it follows, that different HPV types cause warts and papilloma in very different 
anatomical sites, like the genital region or in the oral cavity. The risk of these benign tumours 
to turn into a malign form depends highly on the HPV type, so that different HPV types are in 
addition divided into a high-risk and a low-risk group (Bernard et al., 2010), (de Villiers et al., 
2004). 
 
 
1.1. Clinical data 
The primary way of HPV transmission is during sexual practices, so that most people are 
infected soon after their onset of sexuality. An HPV infection is the most common viral 
infection of the reproductive tract and the fact that simple skin-to-skin genital contact is enough 
for transmission, explains the high infection rates in human populations all over the world. 
(Kjaer et al., 2001). 
Especially women, who are in danger of developing cervical cancer due to an HPV infection, 
are the object of studies on HPV infections and it got clear that HPV infections prevail most 
notably in countries with a lower average-income. This brings Africa and Central America to 
the top of the list with more than 20% of women carrying an HPV infection (Figure 1). In 
Europe, on the other hand only 6.6% of women are infected. The WHO explains this situation, 
with better education about sexual practices and more frequent use of condoms in developed 
countries (Crow, 2012). 
9 
 
More often than not, HPV infections are asymptomatic. The infection will clear itself 
spontaneously without any treatment usually within a few months, so that about 90% of the 
patients are clear of the virus within 2 years. In some few cases, genital warts are formed and 
although hardly resulting in the death of the patient, should these be treated with care, as they 
are highly infectious. On the other hand, certain infections with high-risk HPV types (most 
commonly 16 and 18) might persist and lead to precancerous lesions and, if left untreated, 
progress to cancer (Moscicki et al., 2006).  
 
 
Figure 1: Percentage of women carrying an HPV infection broken down for every continent 
This figure shows the percentage of women being infected with HPV broken down for every continent. It gets 
clear that HPV infections prevail most notably in countries with a lower average-income, making Africa and 
Central America top of the list with more than 20% of women carrying an HPV infection. In Europe, on the 
other hand, with its higher level of development the amount of women with an HPV infection is only 6.6%, 
that is almost a fourth less, than in Africa. The WHO explains this situation, with better education about sexual 
practices and more frequent use of condoms in developed countries. 
The figure also provides information on the most prevalent HPV types found in infected women. With HPV 
16 being the most common HPV type on every continent. It also states additional risk factors for a HPV 
infection to process to cervical cancer. 
(Crow, 2012) 
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The most common cancer type resulting of an HPV infection is cervical cancer (Figure 2) and 
almost all cases can be traced back to an initial HPV infection (Walboomers et al., 1999). 
Typical symptoms appear only in an advanced stage, when the tumour grows bigger due to 
ulceration and these might include irregular and abnormal vaginal bleeding, back, leg or pelvic 
pain and vaginal discomfort (Crow, 2012). 
According to the WHO, of all the types of HPV at least 13 are cancer-causing (high-risk types) 
and two of these types alone, HPV 16 and 18, are responsible for 70% of precancerous cervical 
lesions and cervical cancers. Cervical cancer is the fourth most common cancer in women 
worldwide and in the year 2012 alone, 530 000 new cases were estimated, while in the same 
year, roughly 270 000 patients died. This accounts for 7.5% of all worldwide cancer deaths 
(GLOBOCAN, 2012), (Crow 2012). 
 
 
 
In high-developed countries, where women are screened for precancerous lesions, 80% of 
cervical cancers are prevented, as cervical cancer develops slowly (15 – 20 years) and 
precancerous lesions can be treated. However, in developing countries, where programs to 
screen women are missing, the disease frequently advances until symptoms develop, with the 
Figure 2: Average annual rates of HPV-attributed cancers in the USA 
From this figure, it becomes clear how high the percentage of HPV-attributed cases in different cancers is. 
Especially cervical and vaginal cancers, but also penile cancers are virtually always connected to an HPV-
infection. In vulva cancers, about 50% of the cases can be connected to HPV. This numbers show how 
important a prevention of HPV infection is in order to decrease the cancer cases in the genital area. 
This figure also shows the correlations of occurrence of different cancer types of the genital area, with cervical 
cancers occurring about three times more often than the second numerous cancer type, vulva cancer. 
(Centers for Disease Control and Prevention, USA) 
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prospects for these late-stage cases often being poor. Globally 52% of cervical cancer patients 
die, with the majority of these being residents of developing countries (Shieh et al., 2016). 
There is growing evidence that HPV infections are also linked to other cancer forms, for 
example to cancer of the anus, vulva, vagina and penis (Figure 2), although those cases occur 
very scarcely compared to cervical cancer (Bansal et al., 2016). 
Today there are different vaccines available, with the newest (nine-valent vaccine) having the 
potential to prevent almost 90% of cervical cancers as it grants a protection against nine high-
risk HPV types (6, 11, 16, 18, 33, 45, 52 and 58) (Joura et al., 2015). Clinical trials showed that 
the vaccines are very effective and should be used before the first sexual intercourse, as they 
cannot treat HPV infections or HPV associated diseases. A vaccination of girls in the age 
between 9 and 13 years is seen as the most cost-effective way to deal with cervical cancer 
(WHO), as this reliably prevents the girls from developing cervical cancer. Some countries 
started to vaccinate boys as well, as this helps to prevent genital warts and by that, the fast 
spread of the virus (Harper et al., 2006), (Villa et al., 2006), (Villa et al., 2005). 
There is, as illustrated above, a huge problem with HPV-attributed cancers worldwide and some 
cancer types are even on the rise, according to the Annual Report to the Nation on the Status of 
Cancer (Jemal et al., 2013). The fact that people tend to be suspicious with vaccines, as they 
fear them to cause severe sicknesses, is counterproductive and does not help to lower the 
occurrence of HPV-attributed cancers (Bratic, 2016). 
This means that there is an unmet medical need for a supplement that is able to stop a prevailing 
HPV infection and eliminates the virus from the patient’s body. This would not only help to 
curtail the worldwide HPV infection cases, but also to prevent the thousands of cases of cancer 
in the genital area every year. 
 
 
1.2. HPV genome 
Human papillomaviruses are 45 – 55 nm in size and lack a cap. Their DNA is double-stranded, 
circular and almost 8 000 base pairs long. Even though a family with many representatives, 
show the genomes of the different HPV types a high grade of similarity and they can be 
separated into three distinct segments (Figure 3). The early region (E), which covers roughly 
50% of the viral genome, is the biggest of these and contains the open reading frames for 
proteins, expressed early in the lifecycle of HPV. E1 is a DNA helicase necessary for HPV 
replication and E2 is a regulatory protein, which controls viral gene expression, replication and 
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segregation.  E5, E6 and E7 are oncoproteins, whose function lies in the transformation process 
and, last, E4, which controls the release of the virions.  
The second largest segment is the late region (L), which covers about 40% of the genome and 
contains the reading frames for the L1 and L2 proteins. These are structural proteins and encode 
the proteins of the virion’s cap.  
 
 
 
 
 
The smallest part is the upstream regulatory region (URR), which spans around 10% of the viral 
genome and includes promotor and enhancer elements, as well as the viral origin of replication. 
It controls the early gene transcription and replication (Lee and Laimins, 2007), (de Villiers et 
al., 2004), (Stanley, 2012). 
Figure 3: Genome organisation of HPV type 16 
All HPV types share a similar genome organization. It is separated into three distinct regions: The early (E; 
blue) region, the late (L; green) region and the upstream regulatory region (URR; yellow).  
The early region contains the open reading frames of proteins expressed early in the life cycle of the virus. 
Among these are E5, E6 and E7, the oncoproteins, which operate the transformation process, E1 and E2, which 
are regulatory proteins of the transcription and E4, which controls the release of the virions. 
The late region contains the open reading frames of the two capsid proteins: L1, the major and L2, the minor 
capsid protein. 
The upstream regulatory region controls the early gene transcription and replication and contains promotor 
and enhancer elements, as well as the viral origin of replication. 
As all HPV transcripts are polycistronic, are AE and AL the common polyadenylation sites of the early or 
respectively the late region. 
(Stanley, 2012) 
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1.3. Life cycle of HPV 
 
 
 
 
As the genome of HPV is of very limited size, it is clear that HPV highly depends on proteins 
and factors of the host cell to complete its life cycle (Figure 4). Without them HPV is neither 
able to maintain viral genome copy numbers in undifferentiated cells nor to amplify viral 
genomes in differentiated cells (Moody and Laimins, 2010).  
Human papillomaviruses infect stratified squamous epithelia, where the basal layer became 
exposed after an injury (Culp et al., 2006). The viral genomes remain in basal cells as 
extrachromosomal plasmids and replicate together with the host’s DNA during S-phase and this 
proceeds into the G2-phase as well (Wang et al., 2009), (Reinson et al., 2013), (Reinson et al., 
2015). After entering the nucleus of basal cells, the viral genome copy number increases swiftly 
until about 50 – 100 copies per cell are reached (initial amplification) (Peh et al., 2002). Now 
this number is maintained continuously through the infection (maintenance replication) 
(Penrose and McBride, 2000), until the host cell starts to differentiate (Bedell et al., 1991). 
Figure 4: HPV life cycle 
This figure shows the complete life cycle of HPV from infection until virion release.  
To establish a perpetual infection, HPV needs to infect a cell in the basal layer of a stratified epithelium. 
This is possible via micro lesions. After reaching the host cell’s nucleus, early viral genes are expressed. 
These include E1 and E2, the viral replication factors, and E6 and E7, the viral oncogenic proteins. In this 
basal layer cells the replication rate of viral genomes is kept low and can persist over a long period. Only 
upon cell differentiation, late HPV genes are expressed and then in the outer parts of the epithelium virions 
assembled and released. 
(Moody and Laimins, 2010) 
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Then the vegetative amplification takes place, which means a high-level replication of viral 
genomes (Figure 5). At the same time capsid protein production is initiated (Schwartz, 2013), 
which leads to virion assembly and then, virion release. It is crucial for the process of 
amplification that the differentiating cell remains in an active cell cycle, as HPV genomes only 
are amplified during host cell replication (Galloway and Laimins, 2015).  
 
 
 
 
 
One part of the host’s cell cycle that is required for the genome amplification of high-risk HPV 
types is the ataxia telangiectasia mutated (ATM) pathway (Moody and Laimins, 2009). 
Normally, this pathway works as a tool to repair double strand breaks, but in with HPV infected 
cells, factors of this pathway are constitutively activated and recruited to the HPV genomes 
(Gillespie et al., 2013).  
 
 
 
 
Figure 5: HPV genome copy number variation throughout the infection 
The number of HPV genomes varies highly throughout the different stages of an HPV infection. Right after 
infection, it rises swiftly to 50 – 300 copies per cell. This phase is called the initial amplification. During 
maintenance replication the replication rate is kept low and the copy number kept stable. Only upon host cell 
differentiation a steep increase in the replication rate and thus copy number can be seen. The produced copies 
of the HPV genome are then packed into virions and released. 
(Fisher, 2015; modified) 
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1.3.1. E1 and E2, viral replication proteins. 
Two replication proteins, E1 and E2, are required in all life stages of HPV to execute viral 
replication (Egawa et al., 2012). E1 is a replicative helicase and E2, besides other functions, 
recruits E1 to the replication origin of the viral genome (Mohr et al., 1990), (Ustav and 
Stenlund, 1991), (Ustav et al., 1991). The origin is situated in the upstream regulatory region 
(URR) of the viral genome and contains binding sites for E1 as well as for E2 (Ustav et al., 
1991). With the help of E2, E1 binds to the replication origin and, after E2 left the site, unwinds 
the DNA. Now the replication machinery of the host is used to replicate the viral DNA (Sanders 
and Stenlund, 1998). 
 
 
1.3.2. E6 and E7, viral oncogenic proteins 
These proteins make sure that the environment in the host cell stays suitable for viral replication. 
They promote cellular proliferation, delay cellular differentiation and help HPV to escape the 
immune system of the host (McLaughlin-Drubin et al., 2012). Without them a productive 
replication is impossible (Flores et al., 2000), (Chow et al., 2009). 
E6 causes, amongst other things, a degradation of p53 by recruiting the cellular ubiquitin ligase 
E6AP, which leads to a ubiquitination of p53. Normally, p53 arrests cells after DNA damage 
in order to make a reparation possible (Chen et al., 1995). In addition, the E6 proteins from 
high risk HPV types contain PDZ (acronym combining the first letters of three proteins – 
PSD95, Dlg1, zo-1) binding domains, which allow them to interact with other PDZ domain 
containing factors, which control differentiation and cell polarity (Ganti et al., 2015).  
HPV host cells, keratinocytes, exit the cell cycle at the onset of differentiation. But an active 
cell cycle is needed in order to replicate the HPV genome. That is why the viral oncogene E7 
induces the degradation of pRB family proteins, which in turn allows the cell, through the 
release of E2F, to enter the S-phase of the cell anew. E2F factors are involved in cell cycle 
regulation and DNA synthesis and are with the help of E7 constitutively active (Münger et al., 
1991), (Huh, et al., 2007). 
In HPV-induced cancers, both oncogenic proteins are usually expressed, where they 
synergistically promote oncogenesis. Apart from being essential for providing a suitable 
environment for HPV, they are also essential for an HPV infection to turn into cancer (Mesri et 
al., 2014). 
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1.3.3. Initial amplification 
HPV enters a dividing cell of the basal layer of the epithelium through micro-lesions and its 
genome is transported is transported to the nucleus (Culp et al., 2006), (Day, et al., 2004). After 
entry, the HPV genome is amplified and the viral genome copy number reaches up to a few 
hundred copies per cell (Figure 5) (Peh et al., 2002). 
During this stage, HPV replication is controlled by the E8^E2 protein. This protein is a repressor 
of viral transcription and replication and might help to prohibit a too high level of viral genome 
replication. This is useful in order to keep cellular viability stable and to avoid detection by the 
immune system (Stubenrauch et al., 2000). 
 
 
1.3.4. Maintenance replication  
During this phase, the viral genomes replicate during S-phase by average once per cell cycle 
with the host’s genome in order to keep a constant copy number (Hoffmann et al., 2006). HPV 
replication could be controlled, during this stage, by different mechanisms. The E1 protein is, 
for example, outside of the S-phase, kept in the cytoplasm (Fradet-Turcotte et al., 2010) and 
might even be obsolete during maintenance replication (Egawa et al., 2012). E8^E2 is another 
key protein in the replication rate control mechanism and regulates both transcription and 
replication, by strongly repressing the activity of the viral early promoter. This repression is 
totally independent of E2 (Stubenrauch et al., 2000).  
It was shown that in BPV1 also the phosphorylation of E2, which recruits E1 to the replication 
site, is a limiting factor during the maintenance replication (Penrose and McBride, 2000). This 
could also be true for different HPV types and is for this thesis especially of interest, as a protein 
kinase CK2 inhibitor is used to inhibit HPV replication. 
Following to replication, HPV genomes are equally divided between the daughter cells. It is 
stated that E2 binds to several E2 binding motifs in the viral URR while binding to the host 
chromatin as well. This would ensure a distribution of the HPV genomes between the daughter 
cells (Ilves et al., 1999). While BPV1 is mostly used as a model for viral gene distribution in 
papillomaviruses, most likely, this process applies to all PVs, with only a few small differences 
(McBride et al., 2006). 
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1.3.5. Vegetative replication  
The third HPV genome replication stage – vegetative amplification takes place in differentiated 
keratinocytes. During this stage, HPV genomes undergo rapid amplification and genome copy 
number reached up to a few thousand copies per cell (Bedell et al., 1991). This rapid 
amplification is possible due to the activation of late promoter which results in high levels of 
E1 and E2 protein (Burnett et al., 1990). 
Additionally, the expression of the capsid proteins is initiated. This is regulated through 
differentiation-dependent changes in polyadenylation site usage and through alternate splicing 
(Schwartz, 2013), but also microRNAs from the host cell are used to regulate processes in this 
phase (Cai et al., 2006). These processes include a variety of pathways involving proliferation, 
differentiation and innate immune surveillance. As a large number of these cellular microRNAs 
are modified by viral proteins, one can expect the regulation to be highly complex 
(Gunasekharan and Laimins, 2013). 
 
 
2. U2OS cell line 
U2OS cells are derived from moderately differentiated osteosarcoma, they have an adherent 
epithelial morphology and express the genes for pRb and p53 (Pontén and Saksela, 1967), 
(Niforou et al., 2008).  
Although HPV genomes were already isolated for a quite long period of time, the investigation 
of HPV was hindered by a missing adequate model system, due to HPV’s complex life cycle.  
HPV highly depends on the differentiation of basal epithelial cells to keratinocytes and uses 
mainly the host’s replication machinery, as itself expresses only two replication factors (see 
chapter 1.3 Life cycle). 
For studies on basic mechanisms of animal papillomaviruses the mouse fibroblast cell line C127 
was used, as it is able to maintain PV genomes as free plasmids at a constant number. This 
method, however, is not suitable for researching differentiation specific functions of HPV (Law 
et al., 1981). This is possible in human cell lines only, but most established and widely used 
human cell lines do not support HPV genome replication. As one possible reason for this, a lack 
of regulated expression of viral proteins from the HPV genome, was stated (Geimanen et al., 
2011). 
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After analysing different human cell lines for their ability to support E1 and E2 dependent 
replication and to maintain HPV genomes as extrachromosomal plasmids, it got clear that the 
U2OS cell line is especially suitable for this. This is true, as it also allows the investigation of 
events leading to amplification of the viral genome, which occurs in the later stages of the life 
cycle of HPV (Geimanen et al., 2011). 
Another way to study the life cycle of human papilloma viruses it through infecting primary 
keratinocytes. However, these cells have to be transformed by the virus, thus only oncogenic 
HPV types could be studied. As U2OS cells do not have to be transformed by HPV, they allow 
to study the life cycle of high-risk, low-risk and cutaneous HPV types (Geimanen et al., 2011).  
 
 
3. Protein kinase CK2 
The protein kinase CK2 (casein kinase 2) is a serine/threonine kinase, which is constitutively 
expressed in mammalian cells and phosphorylates a number of substrates. Through this, CK2 
takes part in many cellular processes, such as cell cycle progression, apoptosis, transcription 
and viral infection (St-Denis and Litchfield, 2009). 
This being said, it becomes clear, that the name ‘casein kinase’ is misleading, as this enzyme is 
a protein kinase, which is not linked to casein in the kinome. This situation facilitates the 
confusion with the genuine casein kinase G-CK, which really is responsible for the 
phosphorylation of casein (Tagliabracci et al., 2012). 
When extracted from living tissues, CK2 is a heterotetrameric holoenzyme (Figure 6), 
consisting of two catalytic () and two regulatory () subunits (Hathaway and Traugh, 1979). 
The catalytic subunit exists in two isoforms:  (CK2) and ’ (CK2’), with the latter isoform 
being less common. Although highly homologous, two separate genes encode the two forms 
(Ackermann et al., 2005) and usually both genes are active, with their relative expression 
depending on the tissue type (Xu et al., 1999). 
As CK2 is a constitutively active enzyme, the regulatory  (CK2) subunit rather plays a role 
in determining substrate specificity, with different substrates having a different effect on the 
enzyme’s phosphorylation efficiency (Pinna, 2002), but due to a lack of homology between the 
CK2 and other known proteins (Jakobi et al., 1989), it is rather difficult to ascertain it’s role. 
After individual CK2 subunits were analyzed in living cells, dynamic events were documented, 
which means that different multi-molecular assemblies of this enzyme are possible. The 
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majority of the subunits is not bound to a holoenzyme but moving freely and also entering the 
nucleus individually, not in the form of a pre-assembled holoenzyme (Filhol et al., 2003), 
(Filhol et al., 2005).  
The minimal consensus sequence of CK2 is S/T-X-X-Acidic, so that it phosphorylates serine 
and threonine residues proximal to acidic amino acids (Pinna, 1990), wherefore it can use both, 
ATP and GTP as a phosphate donor (Allende and Allende, 1995). 
One important function of CK2 is that it works as a global anapoptotic agent, which means that 
it is strongly involved in the regulation of the cell death ratio (Ruzzene and Pinna, 2010). From 
this is follows that CK2 is more abundant in cancers, as an unbalanced cell death and survival 
ratio is characteristic for cancerous cells (Guerra and Issinger, 1999). This fact highlights the 
importance of CK2 in anti-cancer drug research and after developing several CK2 inhibitors, 
one of them, CX-4945 (systematic name: 5-[(3-Chlorophenyl)amino]benzo[c][2,6] 
naphthyridine-8-carboxylic acid; also known as Silmitasertib), reached the clinical trial phase 
(Pierre et al., 2011). 
 
 
 
 
Figure 6: 3D Structure of the protein kinase CK2  
The 3D structure of the protein kinase CK 2 holoenzyme as provided from the RCSB Protein Data Bank.  
The holoenzyme consists of 4 subunits, with two being regulatory () and two being catalytic (). 2 isoforms 
of the catalytic subunit has been documented ( and ’), which are highly homologous, yet still encoded in 2 
separate genes.  
(PDB code 4MD8) 
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3.1. CK2 and HPV 
It was stated that several viruses, amongst other also HPV, use phosphorylation of different 
proteins by CK2 in different stages of their life cycle (Firzlaff et al., 1989). This 
phosphorylation can have various affects, with one of them being regulation of viral enzyme 
activity. The inhibiting activity of HPV’s oncogenic protein E7 on the DNA binding activity of 
TATA-Box binding proteins (TBP) is, for example, increased after phosphorylation by CK2. 
This results in a drop of TBP DNA binding activity and explains the inhibitory effects of E7 on 
transcription (Maldonado et al., 2002). 
Furthermore, it is shown that the E1 and E2 proteins are regulated by a phosphorylation of the 
protein kinase CK2. While these findings were mainly done in bovine papilloma viruses (BPV), 
they seem to be valid for several HPV types as well, as multiple possible phosphorylation sites 
are also found in the amino acid sequences of the E1 and E2 proteins of several HPV types 
(Schuck et al., 2013). This is of great significance, as it implies that phosphorylation by CK2 
could have an effect on the life cycle of HPV. Different phosphorylation patterns of the 
replication proteins E1 and E2 might influence the activity of the protein through the rate of 
viral genome replication. If this consideration would be proven to be correct then, through a 
change in CK2 activity, it would be possible to lower the HPV replication rate and maybe even 
to hinder it totally. 
 
 
4. Enzyme inhibitors 
Enzyme inhibitors are molecules that bind to enzymes and by this decrease the enzyme’s 
activity. There are different types of inhibition, which can be reversible or irreversible. If the 
inhibitor binds non-covalently to the enzyme, then the inhibition is reversible. The inhibition is 
irreversible, if it reacts with and alters the enzyme. The mechanisms of inhibition are manifold, 
with typically the inhibitor stopping the substrate from entering the reaction site or hindering 
the enzyme to catalyse the reaction (Berg et al., 2002). 
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4.1. CX-4945 (Silmitasertib) 
A downregulation of the protein kinase CK2, which is overexpressed in many cancers, leads to 
a reduction of cancer cell viability and an increase in the apoptosis rate (Faust et al., 2000), 
(Wang et al., 2001). Thus, CK2 inhibitors could be used as anti-cancer drugs. The first CK2 
inhibitor was developed by Cylene Pharmaceuticals Inc. and is known under the abbreviation 
CX-4945 (Figure 7), or under its trivial name Silmitasertib (systematic name: 5-(3-
chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid). Today an orally administered 
drug based on this compound is in the second phase clinical trials for cancer treatment 
(Siddiqui-Jain et al., 2010), (Pierre et al., 2011). 
Silmitasertib is thought to establish polar bonds with hydrophobic residues in the small and flat 
binding site of the active configuration of the α as well as the α’ subunit of the protein kinase 
CK2. If measured, Silmitasertib and CK2α show a strong interaction, with the dissociation 
constant of the inhibitor being Ki=0.38. This strong binding results in a reduction of enzyme 
activity and through that in altered phosphorylation patterns downstream of CK2 (Sarno et al., 
2005), (Ferguson et al., 2011). 
 
 
 
 
Figure 7: structural formula of CX-4945 (Silmitasertib) 
This ATP-competitive inhibitor of the α and of the α’ subunit of the protein kinase CK2 has as an anti-
cancer drug already reached the second clinical trial phase. Due to its strong binding with the binding 
site of CK2α and CK2α’ it leads to a drop in CK2 enzyme activity and through this to altered 
phosphorylation patterns. 
(Siddiqui-Jain et al., 2012) 
 
22 
 
Experimental section 
1. Objectives 
The principal objective of this thesis is to understand the role of the protein kinase CK2 in the 
life cycle of human papillomaviruses: 
 First it is shown that the protein kinase CK2 has a general effect on the replication of 
HPV genomes, by using U2OS cell lines defective for the regulatory (α) subunit of CK2. 
 After the confirmation, that CK2 indeed has an impact on HPV genome replication, the 
question arose, if E2, the transcriptional regulator of HPV, is still able to downregulate 
HPV gene expression if the regulative (α) subunit of CK2 is defective. 
 Due to the effect of a defective regulatory (α) subunit of CK2 on the HPV replication, 
a CK2 inhibitor (CX-4945) was tested, as it is a possible drug candidate against HPV. 
Its IC50 was determined. 
 As a drop in CK2 activity resulted in a drop in HPV genome replication, the reverse 
experiment was to be conducted, in order to show the general significance of the results. 
This was planned by doing an overexpression of the regulatory (α) subunit of CK2, as 
well as by a rescue experiment with expressing the regulatory (α) subunit of CK2 from 
plasmids in the defective U2OS lines. 
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2. Material and methods 
2.1. Cell culture 
Former works of the Ustav group showed that U2OS cells are a good system to study different 
stages of an HPV infection (Geimanen et al., 2011). Thus are all cell lines used for this thesis 
based on the U2OS cell line which is derived from the osteosarcoma of a young girl. U2OS 
cells were obtained from the American Type Culture Collection (ATCC no: HTB-96). Apart 
from the U2OS wild type, three other cell lines were used, two of them, named U2OS alpha 
and U2OS prime, were developed in the laboratory of Professor Mauro Salvi from the 
University of Padova. These lines are defective for the  subunit of the protein kinase CK2 by 
CRISPR/Cas. The  subunit exists, as mentioned above, in two highly homologous forms ( 
and ´) and the two cell lines, respectively, are not able to produce functional proteins of either 
the  (U2OS alpha) or the ´ (U2OS prime) subunit. The forth cell line that is used is the U2OS 
EBNA cell line, which contains stably the gene for the EBNA1 protein. This protein of the 
Epstein-Barr virus (EBV) enables to replicate a plasmid (oriP), which contains an EBV latent 
origin of replication. This replication imitates the replication of the genome of the cell and can 
be used to compare the replication of the genome of the cell with the replication of 
extrachromosomal HPV genomes. 
Different U2OS cell lines were cultured either in IMDM (Iscove’s modified Dulbecco’s 
medium; Naxo OÜ; U2OS wild type and EBNA) or DMEM (Dulbecco/Vogt modified Eagle's 
minimal essential medium; Naxo OÜ; U2OS  and ´) Both media were supplemented with 
FCS (fetal calf serum; final amount 10% of medium), penicillin (100 IU/ml) and streptomycin 
(100 ng/ml). The cells, maintained in sub-confluent conditions, were grown at 37°C and 5% 
CO2, on 100 mm, 60 mm and 6-well (30 mm) dishes, filled with 8 ml, 3 ml or 2 ml of medium.  
 
 
2.2. Transformation using heat shock 
After thawing competent E. coli DH5α cells on ice, 0.5 µg of plasmid DNA were added and 
the mixture kept on ice for another 15 minutes. The heat-shock was executed by incubating the 
cells at 37°C for 3 minutes and then on ice for 1 minute. 750 µl of LB medium were added and 
the cells incubated at 37°C for 30 minutes, before plating them on LB (lysogenic broth) plates 
containing the corresponding antibiotic for selection and then grown overnight at 37°C.  
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The following day, E. coli colonies were picked and grown overnight (37°C and 220 rpm) in 3 
ml of liquid LB medium with a 50 µg/ml concentration of the corresponding antibiotic 
(ampicillin 100, kanamycin 25). 
The next day the samples were centrifuged at 5000 g for 5 minutes and the plasmids extracted 
with the “FavorPrepTM Plasmid Extraction Kit” (Favorgen Biotech Corp.). To check if the 
extracted plasmids were correct, the plasmids were cut with a linearizing enzyme (depending 
on the plasmid) and after that a gel electrophoresis (0.8% TAE gels) was run. 
 
 
2.3. HPV mini-circle preparation 
This procedure was proposed by Kay et al. (2010). 
In order to obtain functional HPV genomes (HPV mini-circles) for transfection, first plasmids 
had to be duplicated in an E. coli cell line (DH5α). Transformation was performed as described 
above. The following day the colonies were picked but then grown in 3 ml of liquid LB (as 
described above) for only about 7 hours. 200 µl of this pre-grown culture were transferred to 
100 ml of TB (terrific broth) medium containing 50 µg/ml kanamycin and The culture was 
grown for 12 – 16 hours at 37°C and 220 rpm. 
The next morning the induction mixture was added, which triggers the outrecombination 
between the attB and attP sites so that the plasmid backbone is removed, which results in a 
mini-circle, resembling the functional viral genome of HPV. This mixture contained 100 ml LB 
medium, 4 ml 1M NaOH and 200 µl filtered 20% L-arabinose. The samples were grown for 8 
hours at 32°C and 220 rpm. 
After this period, the cultures were centrifuged for 15 minutes at 4°C and 5000 g and the mini-
circles extracted using the Nucleobond® Xtra Maxi EF kit (Macherey-Nagel). 
 
 
2.4. Transfection by electroporation 
Per transfection one 100 mm 70-90% confluent plate of U2OS cells was used. The cells were 
washed with 2 ml 1xPBS, then detached through dissolving their extracellular matrix with 2 ml 
trypsin and gathered into a 50 ml tube containing as much medium as trypsin was used to detach 
the cells. After centrifuging for 5 minutes at 20°C and 300 g, the medium was removed and the 
25 
 
cell pellet resuspended in as much medium as it was necessary to execute all the transfections 
(250 µl per transfection).  
The transfection mixture consisted of the plasmid or mini-circle, which was to be transfected, 
and of 50 µg carrier DNA. This mixture was added to the cuvette, as well as 250 µl of the cells. 
A voltage of 220 V and a capacity of 975 µF were applied (Gene Pulse II, Bio-Rad). Right after 
electroporation, the cells were transferred into 2 ml medium, suspended, centrifuged (5 minutes, 
20°C, 300 g) and the pellet was resuspended in 1 ml medium and transferred to a cell culture 
dish of suitable size. 
 
 
2.5. Total DNA extraction 
The medium was removed and the cells were washed twice with 1xPBS. The cells were lysed 
with 0.5 ml Sol IV (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM EDTA, 0.2% SDS; 
supplemented with proteinase K (0.2 µg/ml)) solution and incubated for at least 18 hours at 
37°C.  
An equal amount of phenol-chloroform (1:1) was added and the samples were vortexed twice, 
before centrifuging them for 2 minutes at 16 000 g. The upper phase was transferred into a new 
tube and the DNA was precipitated with 2 volumes of 96% EtOH. Another incubation step at  
-20°C for 15 – 30 minutes was conducted.  
The samples were centrifuged at 4°C for 20 minutes at 16 000 g, afterwards the supernatant 
was removed and the DNA pellet dried. The pellet was resuspended in 300 µl TE (10mM Tris 
ph8.0, 1 mM EDTA) buffer, containing 20µg/ml RNase, vortexed and incubated at 37°C for 45 
– 60 minutes. 
Then the DNA was precipitated by adding NaCl up to a concentration of 200 mM, by adding 
two volumes of 96% EtOH and by incubating at -20°C for 30 minutes. After incubation the 
samples were centrifuged at 4°C for 15 minutes at 16 000 g, the supernatant was removed and 
the pellet washed with 0.5 ml 70% EtOH. Another centrifugation for 3 minutes at 16 000 g was 
executed.  
The DNA was reconstituted in TE (10mM Tris pH 8.0, 1 mM EDTA) buffer. 
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2.6. Episomal DNA extraction – the HIRT method 
The medium was removed and the cells were washed twice with 1xPBS. Then the cells were 
lysed by adding 800 µl HIRT solution (0.5% SDS, 50 mM Tris pH 8.0, 10 mM EDTA) and 
incubating them for 15 minutes at room temperature. Then 200 µl 5M NaCl were added 
dropwise and the dishes incubated at 4°C overnight. 
After collecting the lysate into 1.5 ml tubes, the lysate was centrifuged at 4°C for 25 minutes at 
16 000 g. The supernatant was transferred into new tubes, 600 µl isopropanol were added and 
the probes were incubated at -20°C for 30 minutes. After incubation, the samples were 
centrifuged once more at 4°C for 10 minutes at 16 000 g and the supernatant removed. The 
pellet was suspended in 200 µl Sol IV (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM EDTA, 
0.2% SDS), containing 50 µg/ml proteinase K.  
After incubating at 56°C for 30 minutes an equal amount of phenol-chloroform (1:1) was added, 
the samples were vortexed and centrifuged for 2 minutes at 16 000 g. The upper phase was 
transferred into a new tube and the DNA precipitated by adding twice as much 96% EtOH and 
incubating at -20°C for 30 minutes. 
The samples were centrifuged at 4°C for 10 minutes at 16 000 g, the supernatant was removed 
and the pellet washed by adding 700 µl 70% EtOH and centrifuging at 4°C for 3 minutes at                 
16 000 g. After that the EtOH was removed and the pellet dried for 2 – 5 minutes at room 
temperature and then suspended in TE buffer, containing 20 µg/ml RNase A.  
The samples were incubated at 37°C for 60 minutes. 
 
 
2.7. Southern blot 
If the genetic material for the Southern blot was a total DNA extraction, the DNA amount was 
normalized by the total DNA content. 
In order to eliminate the input DNA, the samples were incubated for at least 12 hours with DpnI 
and with linearizing enzymes (HPV 11: HindIII, HPV 16: ScaI, HPV 18: BglI). Then the DNA 
was separated by gel electrophoresis on a 1% TAE gel in 1xTAE buffer (4-5 h, 70 V or 16 h, 
30 V). The gel was incubated for 30 minutes in Sol A (0.5 M NaOH, 1.5 M NaCl) solution on 
a shaker, in order to denaturize the DNA, and afterwards neutralized for 30 minutes in Sol B (1 
M Tris pG 7.4, 1.5 M NaCl) solution. The transfer of the DNA onto a Hybond-N+ filter 
(Amersham Pharmacia Biotech) was executed for 6–18 hours, using the capillary transfer 
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method in 10xSSC buffer (1.5 M NaCl, 150 mM Na3C6H5O7). The DNA was cross-linked to 
the filter in an UV Stratalinker 1800 (Stratagene). To avoid unspecific binding, the filter was 
pre-hybridized for at least 45 minutes at 65°C with a pre-hybridization solution (30% 20xSSC, 
10% 50xDen, 5% 10%SDS, 200 µg/ml denatured carrier DNA).  
As the hybridisation probe a linearized HPV genome was used, which was radiolabelled using 
the DecaLabelTM DNA Labeling Kit (Fermentas) and α32P-dCTP (“Du Pont NEN”). The filter 
was rinsed in the hybridisation solution for at least 18 hours at 65°C. Afterwards several 
washing steps were conducted. First, was the filter washed twice for 5 minutes in washing 
buffer 1 (2xSCC, 0.1% SDS), followed by 15 minutes in washing buffer 2 (1xSSC, 0.1% SDS) 
and finally twice for 10 minutes in washing buffer 3 (0.1xSSC, 0.1% SDS).  
The filters were kept for about 2 hours in a x-ray cassette (Kisker Biotech) at -80°C and then 
the outcome revealed in a phosphoimager (Typhoon Trio, GE Healthcare) and the resulting 
pictures quantified (Image Quant). 
 
 
2.8. Western blot 
After removing the medium and washing the dishes twice with 1xPBS, lysing solution 
(2xLaemmli (62.5 mM Tris, pH 6.8; 2% SDS; 10% glycerol; 5% 2-mercaptoethanol; 0,001 % 
bromphenolblue), 200mM DDT) was added (300 µl to 60 mm petri dishes; 150 µl to 30 mm 
dishes). The lysate was collected, transferred into 1.5 ml tubes and denatured at 100°C for 10 
minutes.  
After incubation, the tubes were vortexed thoroughly and hold at -20°C for a short time, to let 
them cool down. The samples were run on a 10% acrylamide gel in 1xSDS buffer at 80 V and, 
after the samples passed through the stacking gel (10 – 15 minutes), at 120 V for about an hour 
(resolving gel). A Prestained Protein MW Marker (Thermo Fisher Scientific) was loaded as 
well. 
The transfer of the proteins onto the membrane (Immobilon®-P polyvinylidene difluoride 
membrane (Millipore Coorp.)) took place in a blotter (Trans-blot® SD Semi-Dry Transfer Cell; 
Bio-Rad), where 15 V were applied for 20 minutes. Before the transfer, the gel was incubated 
in Semi-Dry Met (60 mM Tris, 40 mM CAPS, pH 9.6, 15% methanol) for 20 minutes while the 
membrane was activated with methanol and then incubated in Semi Dry Met for 10 minutes. 
Now the filter was washed for 5 minutes in a Western blot washing solution (0.05M Tris pH 
7.5, 0.15M NaCl, 0.1% Tween20), before being incubated in a 5% skimmed milk blocking 
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solution (5% skimmed milk powder, PBS/0.1% Tween20) for one hour. Two 5-minute washing 
steps were conducted, before adding a 2% skimmed milk solution containing the antibody. In 
this solution, the filter was incubated for one hour and afterwards washed three times for                
5 minutes in a Western blot washing solution. If necessary, a 2% skimmed milk solution 
containing the secondary antibody was prepared, the filter incubated in it for an additional hour 
and then, again, washed 3 times. 
The signal was made visible with an ECL (enhanced chemiluminescence) cassette on 
radiographic films (Fuji), by mixing the ECL reagents 1:1 (luminol/enhancer solution, peroxide 
solution; Naxo OÜ) and immediately drizzling the solution all over the membrane. The 
radiographic films were developed after 1, 3 and 10 minutes of exposition. 
 
 
2.9. Dual-Luciferase® Reporter (DLR™) Assay (Promega)  
First, the medium was removed and the cells washed twice with 1xPBS. Now 250 µl of five 
times diluted Passive Lysis Buffer were added into each of the 30 mm petri dishes. After 
incubating for 15 minutes at room temperature and tilting the dishes from time to time, the 
probes were ready to be measured. The system of this assay uses two different luciferases 
(firefly (Photinus pyralis) and Renilla (Renilla reniformis)) in order to measure the amount of 
the protein of interest and normalise the signal of the different samples. 
The cells were transfected with URR-Luc and a non-specific pRL-Tk reporter plasmid, which 
expresses Renilla luciferase, for normalisation. As according to the manufacturer’s protocol, 
first 50 µl of Assay Reagent II (LAR II) was added to 20 µl of the lysate and then the firefly 
luciferase reporter´s luminescence measured with a Glomax 20/20 luminometer (Promega). 
This value correlates directly with the amount of the protein of interest in the lysate. 
Immediately after this first measurement, this reaction was stopped and at the same time, the 
Renilla luciferase reaction was started, by adding 50 µl of the Stop & Glo® Reagent (prepared 
from Stop & Glo® Buffer and 50x Stop & Glo® Substrate (Renilla luciferase)) to the tube. A 
second measurement was conducted. This second luminescence signal was then used to 
normalise the results of the first luminescence measurement. 
 
 
 
 
29 
 
 
3. Results and discussion 
3.1. Effect of the protein kinase CK2 on the replication of HPV 
Schuck et al. showed 2013, that the life cycle of BPV is partly regulated through a 
phosphorylation of the viral proteins E1 and E2 by the protein kinase CK2. As several HPV 
proteins also show possible phosphorylation sites for CK2 (Firzlaff et al., 1989), the theory 
arose that CK2 could also play a role in the life cycle of HPV. 
In order to examine this, wild type HPV genomes (mini-circles) of two high-risk (16 and 18) 
and one low-risk (11) type were transfected into U2OS cell lines (HPV 11: 2µg; HPV 16: 5µg; 
HPV 18: 3µg). The cell lines used were wild type U2OS, as a control, where the expression of 
CK2 is not impaired, as well as two mutant U2OS cell lines, named ‘U2OS alpha’ and ‘U2OS 
prime’ (developed in the laboratory of Professor Mauro Salvi from the University of Padova). 
In these, the gene for the catalytic  (CK2) or respectively for the catalytic ’ (CK2’) subunit 
of the protein kinase CK2 is mutated.  
The cells were grown in IMDM (wild type) or DMEM (U2OS alpha and prime) medium and 
the total DNA was extracted 3, 5 and 7 days after transfection. The extracted DNA was 
incubated for at least 12 hours with linearizing enzymes (HPV 11: HindIII, HPV 16: ScaI, HPV 
18: BglI) and with DpnI, to eliminate the input DNA. After separation of the DNA fragments 
by length on a 1% TAE gel and transfer of the DNA to a filter, a linearized and radioactively 
labelled HPV probe was used to mark the viral DNA fragments. The filters were then revealed 
in a phosphoimager and the resulting pictures quantified All the experiments were conducted 
twice. 
 
The results show that while for HPV 11 (Figure 8) and 18 (Figure 10) the amount of viral DNA 
is drastically higher in the U2OS wild type (blue) as well as in the U2OS alpha line (orange), 
compared to the U2OS prime line (grey). This effect is clearly visible in panel A and was also 
affirmed by quantification (Panel B). 
For HPV 16 (Figure 9), on the other hand, no difference can be spotted in the increase of viral 
DNA between the three used cell lines. 
 
 
 
 
30 
 
 
 
 
 
 
 
 
0
2
4
6
8
3 5 7
q
u
an
ti
fi
ed
 H
P
V
 1
1
 r
ep
lic
at
io
n
 s
ig
n
al
 r
el
at
iv
e 
to
 
th
e 
U
2
O
S 
d
ay
 3
 t
im
e 
p
o
in
t
time [days]
Wild Type
alpha
prime
Figure 8: Replication signal of the HPV 11 in the U2OS wild type and the U2OS alpha and prime cell 
lines (A: Replication signal; Panel B: Quantified replication signal) 
Panel A shows the replication signal of the viral HPV 11 DNA. Lines 1, 2 and 3 show the time points (3, 5, 
7 days) for the wild type cell line, lines 5, 6 and 7 for the alpha line and 9, 10 and 11 for the prime cell line. 
It is apparent that the amount of viral DNA increases in the wild type as well as in the alpha cell line over the 
period of the experiment, while in the prime line this increase is significantly lower. 
This results were confirmed via quantification, with the results being shown in Panel B. The increase in the 
amount of viral DNA for the wild type (blue) and the alpha line (orange) is significantly higher than the 
increase in the prime cell line (grey). The error bars show the standard deviation of the two independent 
experiments, which were conducted. 
A 
B 
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Figure 9: Replication signal of the HPV 16 genome in the U2OS wild type and the U2OS alpha and 
prime cell lines (A: Replication signal; Panel B: Quantified replication signal) 
Panel A shows the signal of the viral HPV 16 DNA. Lines 1, 2 and 3 show the time points (3, 5, 7 days) for 
the wild type cell line, lines 5, 6 and 7 for the alpha line and 9, 10 and 11 for the prime cell line. The results 
show that there is no large difference in the increase of the amount of viral DNA between the three different 
cell lines.  
This results were confirmed via quantification, with the results being shown in Panel B. The increase in the 
amount of viral DNA for the wild type (blue), the alpha (orange) and the prime (grey) cell line do not 
considerably differ from each other. The error bars show the standard deviation of the two independent 
experiments, which were conducted. 
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Figure 10: Replication signal of the HPV 18 genome in the U2OS wild type and the U2OS alpha and 
prime cell lines (A: Replication signal; Panel B: Quantified replication signal) 
Panel A shows the signal of the viral HPV 18 DNA. Lines 1, 2 and 3 show the time points (3, 5, 7 days) for 
the wild type cell line, lines 5, 6 and 7 for the alpha line and 9, 10 and 11 for the prime cell line. It is apparent 
that the amount of viral DNA in the wild type as well as in the alpha cell line is over the period of the 
experiment on a significantly higher level, than in the prime cell line. 
These results were confirmed via quantification, with the results being shown in Panel B. The level of the 
amount of viral DNA in the wild type (blue) and the alpha line (orange) is significantly higher than the level 
in the prime cell line (grey). The error bars show the standard deviation of the two independent experiments, 
which were conducted. 
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These results imply that, as only in the U2OS prime cell line an effect on viral genome 
replication during the initial amplification is visible, the ’ subunit of the protein kinase CK2 
(CK2’) plays an important role in the genomic replication of HPV 11 and 18. If this subunit 
of CK2 is mutated and not fully functional, a far less effective genomic replication is to be 
expected. 
Furthermore, it can be stated, that contrarily to HPV 11 and 18, in HPV 16 the regulatory 
subunit of the protein kinase CK2 does not have an integral role in the genomic replication. A 
mutation of this subunit does not impair viral gene replication whatsoever. A possible reason 
for this is that in HPV 16 another system is used to regulate the viral genome replication and a 
phosphorylation by CK2 is not necessary for a successful replication.  
Another possible explanation is that due to the, in comparison with the other two HPV types, 
considerably lower level of HPV 16 replication in U2OS cells, it was not possible to show the 
influence of the ’ subunit of the protein kinase CK2 (CK2’) on the initial amplification of 
HPV 16. 
The error bars for the HPV 18 type in the U2OS alpha line are exceptionally big, so that an 
influence of the  subunit of the protein kinase CK2 (CK2) on the initial amplification of 
HPV 18 can only be reliably ruled out, after conducting more identical experiments. 
 
 
3.2. Early protein E2 transcription regulation in CK2α deficient cell lines 
Kurg et al. showed in 2010, that E2 is a negative regulator of HPV 18 gene expression and 
strongly reduces the gene expression controlled by the viral full length URR. This fact together 
with the results of the previous experiment (i.e. CK2 is needed for successful viral genome 
replication) might indicate that a phosphorylation of E2 by CK2 could be necessary for E2 to 
work as a regulator of HPV genome expression. 
That is why, a two-luciferase reporter assay was used to investigate if E2 is able to regulate 
transcription in the two CK2α deficient cell lines as well. Three plasmids were transfected 
together with 50 µg of carrier DNA into wild type U2OS, as well as into alpha and prime lines. 
The first plasmid (pRL-Tk; 25 ng) encodes for a Renilla-luciferase product and is used for 
normalization, while the second plasmid (pQMN-H18-E2) was transfected in different 
concentrations (0 ng, 10 ng, 50 ng, 100 ng, 500 ng) and encodes for E2, which is the 
transcriptional regulator of HPV 18. The last one (URR-Fluc; 100 ng) encodes a firefly-
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luciferase product, controlled by the full-length HPV18 URR region. The cells were grown for 
24 hours and then lysed, the substrates of the luciferases added and the luminescence measured 
in a luminometer. The experiment was conducted twice. 
From figure 11 it is easily spotted, that while in the wild type (blue) the luminescence falls with 
a growing amount of transfected E2 plasmid, in both mutated U2OS lines (U2OS alpha: orange 
and U2OS prime: grey), the luminescence stays at a high level. This means that when CK2 is 
not functional, the ability of the E2 protein of HPV 18 to regulate viral gene expression is 
hampered. 
 
 
 
 
 
 
The results of this experiment indicate, that, as expected, CK2 mediated phosphorylation of E2 
is required for E2 to perform as a regulator of viral genome expression, as only with an intact 
version of the regulatory subunit of CK2 (U2OS wild type: blue) a decrease in viral replication 
was detected. No matter how much E2 plasmid was transfected, in those cell lines with a not 
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Figure 11: E2 transcription regulation in CK2α deficient cell lines 
In graph for the U2OS wild type (blue graph) a strong inhibition of viral gene replication is visible with a 
growing amount of transfected E2 plasmid. This is not true for the other two cell lines (orange: U2OS alpha; 
grey: U2OS prime), where the level of replication only fluctuates slightly, no matter how much E2 plasmid 
was transfected. The error bars show the standard deviation of the two independent experiments, which were 
conducted. 
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functioning version of the regulatory subunit of CK2 (U2OS alpha: orange; U2OS prime: grey) 
no inhibition of viral replication is seen.  
Another conclusion to make is that for E2 to perform as a regulator of viral genome expression 
both subunits are relevant. It does not matter, which of the two isoforms of the regulatory 
subunit of CK2 is mutated, in both cell lines the same effect becomes visible and so it can be 
concluded that both are of same importance.  
 
 
3.3. CX-4945 effect on HPV 18 replication 
In order to validate the previous findings, that CK2 plays an important role in the initial 
amplification of HPV, an inhibitor for CK2 (CX-4945) was used in different concentrations (0 
µM, 0.1 µM, 0.19 µM, 0.38 µM, 0.75 µM, 1.5 µM, 3 µM, 6 µM). The appropriate amount of 
inhibitor was added to the medium in the cell culture dishes after transfection. 
2 µg of HPV 18 wild type genomes (mini-circles) were transfected into the U2OS EBNA cell 
line, together with 1 µg oriP and 50 µg of carrier DNA. U2OS EBNA cells stably express the 
EBNA1 protein of the Epstein-Barr virus which can be used to facilitate the replication of oriP, 
as this plasmid contains the EBV latent origin of replication. EBNA1-dependent replication is 
initiated once per cell cycle (Kirchmaier and Sugden, 1995) and thus its replication mechanism 
is different from the amplification of HPV replication and mimics the cellular genomic DNA 
replication. The EBNA1-dependent replication could be thus used as an internal control to 
determine the specificity of the compound.   
The cells were grown for 5 days, with a medium change at the third day (the inhibitor was added 
anew) and then the total DNA extracted. In order to linearize the viral genome and oriP, the 
extracted DNA was incubated for at least 12 hours with ScaI and BstXI, as well as with DpnI, 
to eliminate the input DNA. After separation of the DNA fragments by length on a 1% TAE 
gel and transfer of the DNA to a filter, a radioactive HPV18-specific and a ori-P specific probes 
were used to mark the DNA fragments. The filters were then revealed in a phosphoimager and 
the resulting pictures quantified. The experiment was conducted twice. 
 
The results of the southern blot (Figure 12A) show that the higher the concentration of the CK2 
inhibitor CX-4945 gets, the more the replication rate of HPV 18 declines. Especially the three 
highest concentrations (1.5 µM, 3 µM, 6 µM) cause a noteworthy decline. The EBNA1-
dependent replication rate, on the other hand, is not affected at all and continues at the same 
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pace in all the samples in spite of a growing CX-4946 concentration. This replication mimics, 
as described above, the genomic replication. 
These findings are affirmed after quantification, shown in Figure 12B, where the trend line for 
HPV (blue) drops with growing inhibitor concentration, while the trend line for EBNA (orange) 
even rises. 
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Figure 12: Effect of CX-4945 on HPV 18 replication (A: Replication signal; Panel B: Quantified 
replication signal) 
Panel A shows the signal of the viral HPV 18 DNA, as well as the signal for oriP, which contains an EBV latent 
origin of replication and thus imitates the replication of the genomic DNA of the cell in the U2OS EBNA cell 
line. It is apparent that the signal for HPV 18 weakens with a higher CX-4945 concentration, while the signal 
for oriP (EBNA) remains unaltered. 
These results were affirmed by quantification (Panel B), with the signal of the viral HPV DNA (blue graph) 
declining at higher inhibitor concentrations, while the signal for oriP (orange graph) shows no signs of 
decrement. The error bars show the standard deviation of the two independent experiments, which were 
conducted.  
B 
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The formula for the HPV trend line (y = 0.8716e-0.294x) was used to calculate the IC50: 
 
IC50: 0.5 = 0.8716e-0.294x 
IC50: 1.89 µM 
 
These results validate the outcome of the experiments illustrated above (3.1 Effect of the protein 
kinase CK2 on the replication of HPV) and strengthen the theory that the protein kinase CK2 
is important in the amplification of the viral genome of HPV, as an inhibitor of this kinase is 
able to inhibit viral genome amplification as well. 
These results are even more of interest, as up-to-date, there is no specific treatment of an HPV 
infection available. The protein kinase CK2 inhibitor CX-4945, however, is a potent candidate 
for an anti-HPV drug, as it inhibits selectively the viral genome replication and, as it was seen 
from the results, quite effectively. The host cell genomic replication, on the other hand, is not 
inhibited, as shown by the unaltered replication of oriP even at high inhibitor concentrations. 
This inhibitor is, as mentioned above, already in the second phase of clinical trials as an anti-
cancer drug, which makes the prospects even more promising. 
 
 
3.4. CX-4945 effect on E1 and E2 activity 
To investigate if the protein kinase CK2 has an effect on the ability of the viral proteins E1 and 
E2 to initiate replication from the viral origin of replication, 250 ng of the p18URR plasmid 
were transfected into U2OS wild type cells, together with 25 ng of an E1 (p18 E1) and 25 ng 
of an E2 (p18 E2) coding plasmid. p18URR contains only the upstream regulatory region 
(URR) of HPV 18 and its replicational behaviour is thought to be similar to the behaviour of an 
HPV wild type genome, while p18E1 and p18E2 express E1 and E2 (Dale, 1954) under the 
control of a strong CMV promotor. This experimental set-up allows to examine the replication 
properties of E1 and E2 and to determine if the phosphorylation of these proteins by CK2 is 
necessary for the initiation of HPV replication. 
Different concentrations (0 µM, 1.5 µM, 3 µM, 6 µM) of the CK2 inhibitor CX-4945 were 
added after transfection and episomal DNA was purified after 24 and 48 hours using the HIRT 
extraction method. In order to linearize HPV18URR plasmid, the extracted DNA was incubated 
for at least 12 hours with BglI as well as with DpnI, to eliminate the bacterially produced input 
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DNA. After separation of the DNA fragments by length on a 1% TAE gel and transfer of the 
DNA to a filter, a radioactive HPV18URR-specific probe was used to mark the DNA fragments. 
The filters were then revealed in a phosphoimager and the resulting pictures quantified. The 
experiment was conducted twice. 
A 100 pg control and size-marker (linearized URR H18 plasmid) was loaded on the gel as well. 
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Figure 13: Effect of CX-4945 on E1 and E2 activity (A: Replication signal; Panel B: Quantified 
replication signal)) 
Panel A shows the signal for the linearized pURR18 plasmid, from which it gets clear that there is no significant 
change in the degree of replication even if high concentrations of the casein kinase inhibitor CX-4945 are 
added. The visible variations are to be explained with the technique used (HIRT extraction), where it is not 
possible to normalize the extracted DNA. The bands visible below the pURR18 signal are remains of the input 
DNA, which got digested by DpnI. 
This results were affirmed by quantification (Panel B), where the blue graph shows the p18URR replication at 
different inhibitor concentrations (0 µM, 1.5 µM, 3 µM, 6 µM) after 24 hours of growth and the orange graph 
shows the p18URR replication at different inhibitor concentrations (0 µM, 1.5 µM, 3 µM, 6 µM) after 48 hours 
of growth. The visible variations are, again, to be explained with the technique used (HIRT extraction), where 
it is not possible to normalize the extracted DNA. The error bars show the standard deviation of the two 
independent experiments, which were conducted. 
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Considering the possible unequal amount of DNA loaded (due to HIRT extraction), it can be 
said that there is no significant effect of the inhibitor on the replication visible (Figure 13A). 
The DpnI bands are a result of the input DNA being digested by DpnI. This outcome is also 
supported by the quantification (Figure 13B).  
 
These results show that the protein kinase CK2 has no direct effect on the E1 and E2 dependent 
replication in HPV or, in other words, CK2 does not regulate the transcriptional regulator E1 
and E2´s ability to bind to their binding sites. It rather implicates that CK2 has an effect on the 
ability of E2 to influence HPV 18 gene expression and through that on HPV replication. 
 
 
3.5. Preliminary test: Overexpression of the CK2α and CK2α’ subunits 
The next logical step was to try and overexpress both isoforms of the regulatory subunit of CK2 
(CK2α and CK2α’), in order to investigate if the effect seen in the previous experiments (lack 
of CK2 activity leads to less HPV replication) works also the other way (additional CK2 activity 
leads to more HPV replication?). Also a rescue experiment was planned, where the missing 
activity of the regulatory subunit in the U2OS alpha respectively U2OS prime cell line was to 
be balanced with an expression of those subunits from extrachromosomal vectors. 
In order to conduct these experiments, CK2α and CK2α’ expressing plasmids were needed and 
these were sent by Professor Mauro Salvi from the University of Padova. First it had to be 
shown that those plasmids effectively express CK2α and CK2α’ in U2OS wild type cells. 
Different amounts of CK2α respectively CK2α’ expressing plasmids (0 ng, 100 ng, 500 ng, 
1000 ng) were transfected into U2OS wild type cells. The cells were grown for 24 hours and 
then a western blot performed.  
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As seen from Figure 14, only the CK2α subunit is solidly expressed, while for CK2α’ no signal 
could be detected. This means that in order to perform further experiments, first, a functional 
CK2α’ expressing plasmid needs to be created. 
 
 
 
 
 
 
 
 
 
Figure 14: Overexpression of CK2α and CK2α’ in U2OS cells 
As it is seen from the figure, CK2α is detectable for all three plasmid amounts used (lines 2, 3 and 4). While 
the signal for 100 ng is very low, with 500 ng as well as 1000 ng a strong signal is seen. No signal was 
detectable for CK2α’ (lines 6, 7 and 8), no matter how much plasmid was transfected (L – ladder (Prestained 
Protein MW Marker) (line 8); both proteins ~42 kDa; exposition time: ~15 minutes). 
 
[ng] 
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4. Outlook 
The results of this thesis offer a lot of suggestions for further experiments. More experiments 
need to be conducted, to assure the importance of the protein kinase CK2 for HPV replication. 
These experiments could be, for example, an overexpression of the regulatory subunit of CK2, 
or a rescue experiment with CK2α and CK2α’ expressing plasmids in the CK2α defective cell 
lines. Other possible experiments are a CK2 knock-out with siRNA or a mutation of the active 
sites of the protein kinase CK2. 
After assuring the observed effect of CK2 on HPV replication, it could be investigated how 
exactly this mechanism works and where exactly the protein kinase CK2 is needed in HPV 
replication. This could be achieved by mutating the casein kinase CK2 sites in E2 or in other 
HPV proteins. 
Moreover, all the experiments were performed during HPV’s initial amplification only. It would 
be of interest to examine if CX-4945 also is able to inhibit HPV replication during maintenance 
and vegetative replication in the later stages of HPV’s life cycle. 
Most certainly, the long-term goal of experiments on the effect of CX-4945 on HPV replication 
is the development of an anti-HPV drug, because currently there is none available. 
Another question this thesis might offer an answer to is that, thus far, the HaCat cell line, which 
are immortal keratinocytes, did not prove to be a good model system for studies of HPV, 
although this cell line should provide a more natural environment for the virus. One hypothesis 
could be that, as CK2 activity has proven to be of high importance for both replication and 
translation, this could be the limiting factor for HPV replication and CK2 activity might be too 
low in HaCat cells. One way to prove this hypothesis is to co-transfect HPV genomes and CK2 
expression plasmids into HaCat cells. If the hypothesis is correct then this should enable HPV 
to persist also in HaCat cells at a higher level.  
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Summary 
To summarise this thesis, it can be said that the protein kinase CK2 indeed has a noteworthy 
effect on the replication of HPV. This is true for the HPV types 11 and 18 and propably for 
other types as well, but further experiments need to be performed to investigate that.  
In addition, it was shown that the regulatory subunit of CK2 (CK2α) is the part that plays the 
important role in the dependence of HPV on CK2, with especially the α’ subunit being of 
significance. The level of viral genome replication is at a significantly lower level, if this 
subunit is defective. 
Another outcome of this thesis is that the viral replication protein E2 needs CK2 
phosphorylation in order to work as a negative regulator of viral genome replication. Although 
CK2 phosphorylation has no direct effect on E1 and E2 dependent replication in HPV, it seems 
to have an influence on E2’s ability to influence HPV gene expression and through that on HPV 
replication. 
Furthermore, CX-4945, a protein kinase CK2 inhibitor, was successfully used to inhibit the 
replication of HPV 18 during the initial replication phase. This inhibition seems to be selective 
for viral genome replication as the replication of another plasmid (oriP), which mimicked 
genomic replication, was not affected. With a determined IC50 of 1.89 µM, this compound could 
be a possible solution to meet the need of an anti-HPV drug. The fact that CX-4945 reached the 
second phase in clinical trials as an anti-cancer drug makes this finding even more promising. 
 
As an outlook it can be stated that the results of this thesis offer a lot of suggestions for further 
experiments. Not only are more experiments needed to assure the findings of this thesis, but 
also to investigate the mechanism behind these findings.  
Additionally, the results presented in this thesis might offer an explanation for the weak 
replication levels of HPV in HaCat cells which should offer this virus a more natural 
environment. More experiments are needed, to examine if the CK2 levels in HaCat cells are in 
fact lower than in U2OS cells. 
All these suggested experiments are very interesting from the point of understanding the 
mechanisms of the life cycle of HPV, but the long-term goal should be the development of the 
first anti-HPV drug. This would help to prevent many cervical cancer cases, which are the 
reason for many cancer deaths worldwide. The results of this thesis show that CX-4945 is a 
promising candidate for this undertaking and more experiments are needed to bring this to a 
successful end. 
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Proteiinkinaas CK2-e roll inimese papilloomiviiruse elutsüklis 
Matthias Mauch 
Kokkuvõte 
Peaaegu kõiki emakakaelavähi juhtumid saab taandada varasemale infektsioonile erinevate 
inimese papilloomiviiruse (ingl. k.: human papillomavirus, HPV) tüüpidega. Tavaliselt 
paranetakse sellisest infektsioonist iseeneslikult paari kuu jooksul, ilma et sümptomeid üldse 
esineks. Siiski võib harva esineda tüükaid ja teisi healoomulisi vohamisi ning osadel juhtudel 
võib ka emakakaelavähk välja areneda. Emakakaelavähki põhjustavaid HPV tüüpe kutsutakse 
kõrge riskiga HPV tüüpideks. HPV infektsioon on pandeemiline probleem ning sellega 
infitseeritud on  ligikaudu 10% kõikidest naistest. Enim on nakatumisi ja surmajuhtumeid 
maailma vähem arenenud regioonides, kus infektsioonimäär on kõrge ja puuduvad igasugused 
emakakaelavähi sõeluuringuid. Emakakaelavähk on maailmas levimuselt neljas vähiliik ning 
ühes aastas nakatub sellesse umbes 500 000 naist. Samal ajal sureb sellesse 270 000 naist, mis 
moodustab 7,5% kõikidest vähisurmadest maailmas. Tänase päevani on vaktsineerimine ainus 
võimalus HPV vastu võitlemiseks ning hoolimata sellest, et maailmas on suur nõudlus HPV 
ravimi järgi, ei ole seda senini luua suudetud. 
Käesolevas magistritöös viidi läbi erinevad eksperimendid HPV ning proteiinkinaasi CK2-ga. 
Näidati, et proteiinkinaas CK2 on HPV varases replikatsioonis hädavajalik ning ilma selleta ei 
saa HPV oma elutsüklit lõpuni läbida. Samuti suudeti näidata, et CK2-e funktsiooni eest 
vastutab eelkõige proteiinkinaasi CK2 regulatoorne subühik α’. Proteiinkinaasi CK2 inhibiitori 
CX-4945 lisamisega suudeti samuti HPV varast replikatsiooni takistada. CX-4945, 
triviaalnimetusega „Silmitasertib“, reageerib kovalentselt CK2 regulatoorse subühiku 
seondumissaidiga ja omab kõrget dissotsiatsioonikonstanti, mis tähendab, et see inhibeerib 
usaldusväärselt proteiinkinaasi CK2 fosforüleerimist.  
Selle magistritöö tulemused pakuvad ideid paljudele järgmistele katsetele, milles oleks 
võimalik näiteks proteiinkinaasi CK2 täpset seost HPV varase replikatisooniga uurida, ehk kus 
kohas ja millal CK2 oma tööd teeb. Kindlasti on CX-4945 huvipakkuv ka sellepärast, et 
tegemist on potentsiaalse ravimi kandidaadiga, sest see näib olevat tugev inhibiitor HPV 
replikatsioonile ja jõudis vähiravimina juba kliiniliste uuringute teise etappi. 
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